Effects of a respiratory and neurological rehabilitation treatment plan in post Covid-19 affected university students. Randomized clinical study.

IF 3.5 3区 医学 Q2 RESPIRATORY SYSTEM Chronic Respiratory Disease Pub Date : 2024-01-01 DOI:10.1177/14799731241255967
Zacarías Sánchez Milá, David Rodríguez Sanz, Ana Martín Nieto, Ana Jiménez Lobo, Manuel Ramos Hernández, Angélica Campón Chekroun, Raúl Frutos Llanes, José Manuel Barragán Casas, Jorge Velázquez Saornil
{"title":"Effects of a respiratory and neurological rehabilitation treatment plan in post Covid-19 affected university students. Randomized clinical study.","authors":"Zacarías Sánchez Milá, David Rodríguez Sanz, Ana Martín Nieto, Ana Jiménez Lobo, Manuel Ramos Hernández, Angélica Campón Chekroun, Raúl Frutos Llanes, José Manuel Barragán Casas, Jorge Velázquez Saornil","doi":"10.1177/14799731241255967","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>COVID-19 demonstrated the possibility of neurological complications such as loss of sense of smell and taste, together with respiratory problems. Respiratory training and rehabilitation of neurological sequelae are essential to improve respiratory function and thus quality of life, and the aim of this study is to evaluate the efficacy of a pulmonary and neurological rehabilitation program.</p><p><strong>Objectives: </strong>To apply a treatment to reduce dyspnea, increase exertional capacity, increase vital capacity and respiratory muscle strength, together with an increase in olfactory and gustatory sensitivity in post-SARS-CoV-2 patients.</p><p><strong>Methods: </strong>A randomised controlled experimental study was conducted in 220 patients with a medical diagnosis of COVID-19 and more than 5 months of evolution, dyspnoea or perceived fatigue, including olfactory and gustatory perception problems, of whom 200 patients completed the study. 100 patients were randomly assigned to the intervention group, consisting of an inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days, and 100 patients to the control group, for 31 days without any type of therapy.</p><p><strong>Results: </strong>The study was conducted in post-Covid-19 patients for 5 months. Two hundred patients were divided into an intervention group (<i>n</i> = 100) and a control group (<i>n</i> = 100). The comparison between the groups showed significant differences in spirometric variables; forced vital capacity (<i>p</i> < .001; Eta2 (0.439); Mean: 0,6135), the ratio between both FEV1/FVC (<i>p</i> < 0.01; Eta2 (0.728); Mean:9,313), peak inspiratory pressure (<i>p</i> < 0.01; Eta2 (0.906); Mean:4,526); changes were observed in dyspnoea measured with the modified Borg scale (<i>p</i> < 0.01; Eta2 (0.811); Mean:1,481) and the modified Medical Research Council scale (<i>p</i> < 0.01; Eta2 (0.881); Mean: 0.777); finally, changes were found in neurological variables, in the questions of the Singapore Smell and Taste Questionnaire, How was your sense of smell after treatment? (<i>p</i> < 0.01; Eta2 (0.813); Mean: 1,721) and How is your sense of taste after treatment? (<i>p</i> < 0.01; Eta2 (0.898); Mean: 1,088).</p><p><strong>Conclusion: </strong>The implementation of a respiratory rehabilitation treatment plan with the Powerbreathe Plus® device, aerobic exercise and neurorehabilitation with olfactory and gustatory training, is a therapeutic option against respiratory and neurological sequelae in patients who have suffered such sequelae due to the SARS-CoV-2 virus. Clinicaltrials.gov: NCT05195099. First posted 18/01/2022; Last Update Posted 29/06/2022.</p>","PeriodicalId":10217,"journal":{"name":"Chronic Respiratory Disease","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100389/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Respiratory Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14799731241255967","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: COVID-19 demonstrated the possibility of neurological complications such as loss of sense of smell and taste, together with respiratory problems. Respiratory training and rehabilitation of neurological sequelae are essential to improve respiratory function and thus quality of life, and the aim of this study is to evaluate the efficacy of a pulmonary and neurological rehabilitation program.

Objectives: To apply a treatment to reduce dyspnea, increase exertional capacity, increase vital capacity and respiratory muscle strength, together with an increase in olfactory and gustatory sensitivity in post-SARS-CoV-2 patients.

Methods: A randomised controlled experimental study was conducted in 220 patients with a medical diagnosis of COVID-19 and more than 5 months of evolution, dyspnoea or perceived fatigue, including olfactory and gustatory perception problems, of whom 200 patients completed the study. 100 patients were randomly assigned to the intervention group, consisting of an inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days, and 100 patients to the control group, for 31 days without any type of therapy.

Results: The study was conducted in post-Covid-19 patients for 5 months. Two hundred patients were divided into an intervention group (n = 100) and a control group (n = 100). The comparison between the groups showed significant differences in spirometric variables; forced vital capacity (p < .001; Eta2 (0.439); Mean: 0,6135), the ratio between both FEV1/FVC (p < 0.01; Eta2 (0.728); Mean:9,313), peak inspiratory pressure (p < 0.01; Eta2 (0.906); Mean:4,526); changes were observed in dyspnoea measured with the modified Borg scale (p < 0.01; Eta2 (0.811); Mean:1,481) and the modified Medical Research Council scale (p < 0.01; Eta2 (0.881); Mean: 0.777); finally, changes were found in neurological variables, in the questions of the Singapore Smell and Taste Questionnaire, How was your sense of smell after treatment? (p < 0.01; Eta2 (0.813); Mean: 1,721) and How is your sense of taste after treatment? (p < 0.01; Eta2 (0.898); Mean: 1,088).

Conclusion: The implementation of a respiratory rehabilitation treatment plan with the Powerbreathe Plus® device, aerobic exercise and neurorehabilitation with olfactory and gustatory training, is a therapeutic option against respiratory and neurological sequelae in patients who have suffered such sequelae due to the SARS-CoV-2 virus. Clinicaltrials.gov: NCT05195099. First posted 18/01/2022; Last Update Posted 29/06/2022.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
呼吸和神经康复治疗计划对受 Covid-19 影响后大学生的影响。随机临床研究。
背景:COVID-19显示了神经系统并发症(如嗅觉和味觉丧失)和呼吸系统问题的可能性。呼吸训练和神经系统后遗症的康复对于改善呼吸功能从而提高生活质量至关重要,本研究旨在评估肺部和神经系统康复计划的疗效:目的:对 SARS-CoV-2 后遗症患者进行治疗,以减轻呼吸困难、提高用力能力、增加生命容量和呼吸肌力量,同时提高嗅觉和味觉灵敏度:对 220 名医学诊断为 COVID-19 并有 5 个月以上进化、呼吸困难或感觉疲劳(包括嗅觉和味觉问题)的患者进行了随机对照实验研究,其中 200 名患者完成了研究。100名患者被随机分配到干预组,包括吸气训练治疗计划(Powerbreathe Plus®)、有氧运动和嗅觉味觉治疗,为期31天;100名患者被分配到对照组,为期31天,不接受任何类型的治疗:这项研究在科维德-19 后患者中进行,为期 5 个月。200 名患者被分为干预组(100 人)和对照组(100 人)。两组间的比较显示,两组在肺活量测量变量方面存在显著差异;肺活量(P < .001;Eta2 (0.439);平均值:0.6135)、肺活量(P < .001;Eta2 (0.439);平均值:0.61350.6135)、FEV1/FVC 之间的比率(P < 0.01;Eta2 (0.728);平均值:9313)、吸气峰压(P < 0.01;Eta2 (0. 906);平均值:4.906);平均值:4526);用改良博格量表测量的呼吸困难(p < 0.01;Eta2(0.811);平均值:1481)和改良医学研究委员会量表(p < 0.01;Eta2(0.881);平均值:0.777)观察到了变化;最后,用改良博格量表测量的呼吸困难(p < 0.01;Eta2(0.728);平均值:0.777)观察到了变化:0.777);最后,在新加坡嗅觉和味觉问卷的问题 "治疗后您的嗅觉如何?(p < 0.01; Eta2 (0.813); Mean:1,721)和治疗后您的味觉如何?(p < 0.01; Eta2 (0.898); Mean:结论结论:使用 Powerbreathe Plus® 设备实施呼吸康复治疗计划、有氧运动和神经康复治疗,并进行嗅觉和味觉训练,是预防 SARS-CoV-2 病毒导致的呼吸系统和神经系统后遗症的一种治疗方法。临床试验:NCT05195099。首次发布时间:2022年1月18日;最后更新时间:2022年6月29日。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Chronic Respiratory Disease
Chronic Respiratory Disease RESPIRATORY SYSTEM-
CiteScore
5.90
自引率
7.30%
发文量
47
审稿时长
11 weeks
期刊介绍: Chronic Respiratory Disease is a peer-reviewed, open access, scholarly journal, created in response to the rising incidence of chronic respiratory diseases worldwide. It publishes high quality research papers and original articles that have immediate relevance to clinical practice and its multi-disciplinary perspective reflects the nature of modern treatment. The journal provides a high quality, multi-disciplinary focus for the publication of original papers, reviews and commentary in the broad area of chronic respiratory disease, particularly its treatment and management.
期刊最新文献
Quantifying uptake and completion of pulmonary rehabilitation programs in people with chronic obstructive pulmonary disease known to tertiary care. Navigating the COVID-19 pandemic: Experiences and self-management approaches adopted by people with interstitial lung disease. Relationship between dust allergen sensitization and cardiac autonomic function in patients with chronic obstructive pulmonary disease. Respiratory impairments in patients suffering from Fabry disease - A cross-sectional study. Two-year diffusion capacity trajectory in COVID-19 pneumonia survivors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1